Treatment of chronic hepatitis C: Anticipated impact of resistance in patients treated with protease inhibitors

被引：7

作者：

Kronenberger B. ^{[1
]}

Zeuzem S. ^{[1
]}

机构：

[1] Zentrum der Inneren Medizin, Medizinische Klinik 1, 60590 Frankfurt am Main

来源：

Current Gastroenterology Reports | 2009年 / 11卷 / 1期

关键词：

Sustained Virologic Response; Sustained Virologic Response Rate; Telaprevir; Boceprevir; Peginterferon Alfa;

D O I：

10.1007/s11894-009-0003-9

中图分类号：

学科分类号：

摘要：

A main target of specifically targeted antiviral therapy for hepatitis C (STAT-C) is the NS3-protease, which has key functions in the hepatitis C virus (HCV) replication cycle. HCV/NS3-protease inhibitors have shown high antiviral activity in vitro and in patients with chronic hepatitis C. Protease-resistant HCV variants occurred rapidly in patients receiving protease-inhibitor monotherapy. The development of resistance can be best explained by selection of preexisting resistant variants, which grow out under selective pressure. Numerous mutations associated with resistance were identified. Clinical trials showed that protease-resistant strains are sensitive to interferon and that a triple combination of protease inhibitors, peginterferon, and ribavirin may improve the sustained virologic response rate compared with standard peginterferon/ribavirin combination therapy. Overall, it can be anticipated that successful treatment with protease inhibitors will require either combination therapy with peginterferon/ribavirin or a combination of STAT-C compounds with distinct modes of action and resistance patterns. © Springer Science+Business Media, LLC 2009.

引用

页码：15 / 21

页数：6

共 25 条

[21]

Kwo P.Y., Lawitz E., McCone J., Et al., Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC [abstract 995], J Hepatol, 48, SUPPL. 2, (2008)

[22]

Seiwert S.D., Andrews S.W., Tan H., Et al., 750 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development [abstract 750], J Hepatol, 44, SUPPL. 2, (2006)

[23]

InterMune: InterMune Submits CTA Amendment for ITMN-191 and Provides Update on Clinical Development Program, (2007)

[24]

Reesink H., Verloes R., Abou Farha K., Et al., Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: A phase 1 study [abstract 64], J Hepatol, 48, SUPPL. 2, (2008)

[25]

Koev G., Dekhtyar T., Han L., Et al., Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro, Antiviral Res, 73, pp. 78-83, (2007)

← 1 2 3 →